The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Fursova A.Zh.

State Novosibirsk Regional Clinical Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630087

Chubar N.V.

Novosibirsk State Regional Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630008

Tarasov M.S.

Novosibirsk State Regional Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630008

Vasilyeva M.A.

Novosibirsk State Regional Clinical Hospital, Nemirovicha-Danchenko St., 130, Novosibirsk, Russian Federation, 630008

Pustovaya G.G.

Novosibirsk State Regional Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630008

Sayfullina I.F.

Novosibirsk State Regional Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630008

Prognostic factors of antiangiogenic therapy response in neovascular macular degeneration

Authors:

Fursova A.Zh., Chubar N.V., Tarasov M.S., Vasilyeva M.A., Pustovaya G.G., Sayfullina I.F.

More about the authors

Journal: Russian Annals of Ophthalmology. 2018;134(1): 48‑55

DOI: 10.17116/oftalma2018134148-55

Read: 1854 times

Download PDF (RU)
Contact the author
Table of contents

PROGNOSTIC FACTORS OF ANTIANGIOGENIC THERAPY RESPONSE IN NEOVASCULAR MACULAR DEGENERATION
PROGNOSTIC FACTORS OF ANTIANGIOGENIC THERAPY RESPONSE IN NEOVASCULAR MACULAR DEGENERATION

To cite this article:

Fursova AZh, Chubar NV, Tarasov MS, Vasilyeva MA, Pustovaya GG, Sayfullina IF. Prognostic factors of antiangiogenic therapy response in neovascular macular degeneration. Russian Annals of Ophthalmology. 2018;134(1):48‑55. (In Russ.)
https://doi.org/10.17116/oftalma2018134148-55

Подписка 2026 Вестник офтальмологии (Russian Annals of Ophthalmology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Abstract:

The apparent success of antiangiogenic therapy in patients with neovascular age-related macular degeneration (nAMD) shows the significance of effect prognosis and continuous observation. Purpose: to study the influence of prognostic factors on the dynamics of functional and morphological response during anti-VEGF therapy in patients with nAMD. Material and methods. Retrospective analysis of anti-angiogenic therapy results was performed on the data of 1020 patients with nAMD. Some patients were put into two subgroups: 100 patients with retinal pigment epithelium detachment (PED) and 100 patients without PED. Comparative analysis of functional and morphological parameters was performed in the subgroups. Results. Baseline visual acuity (VA) in patients with PED (0.14±0.1) was significantly (р<0.05) lower than in patients without PED (0.32±0.21) and had negative correlation with PED presence (r=–0.61, р<0.05). By the end of the 12 months follow-up Best Corrected Visual Acuity (BCVA) was 0.52±0.28 and 0.62±0.28 (р>0.05) in patients with PED and without PED respectively. Mean number of injections in patients with PED was 5.7±2.5 compared to 3.5±1.2 in patients without PED (р<0.05). After 12 months VA in patients with PED was associated with baseline BCVA (r=0.59, р<0.05), VA after 4th injection (r=0.84, р<0.05) and baseline retinal thickness (r=0.60, р<0.05). Conclusion. PED in patients with nAMD was shown to be an unfavorable factor associated with significantly lower baseline BCVA that requires careful monitoring. At least three “loading” injections are required to determine drug responsiveness and acquire functional and morphological response data. Correlation of BCVA values at different timepoints (baseline/after 3 “loading” doses/after 12 month) was found.

Keywords:

foveolar retinal thickness
ranibizumab
pigment epithelium detachment

Authors:

Fursova A.Zh.

State Novosibirsk Regional Clinical Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630087

Chubar N.V.

Novosibirsk State Regional Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630008

Tarasov M.S.

Novosibirsk State Regional Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630008

Vasilyeva M.A.

Novosibirsk State Regional Clinical Hospital, Nemirovicha-Danchenko St., 130, Novosibirsk, Russian Federation, 630008

Pustovaya G.G.

Novosibirsk State Regional Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630008

Sayfullina I.F.

Novosibirsk State Regional Hospital, 130 Nemirovicha-Danchenko St., Novosibirsk, Russian Federation, 630008

Close metadata

References:

  1. WHO [webpage on the Internet]. Prevention of Blindness and Visual Impairment. Priority Eye Diseases; 2012. Available from: http://www.who.int/blindness/causes/priority/en/index7.html. Accessed May 6, 2016. https://doi.org/10.1038/eye.2011.337
  2. Neroev VV. Russian observational epidemiological interventional study of patients with wet age-related macular degeneration. Rossiiskii oftal’mologicheskii zhurnal. 2011;4(2):4-9. (In Russ.)
  3. Lim LS, Mitchell P, Seddon JM, Holz FG, Wong TY. Age-related macular degeneration. Lancet. 2012;379(9827):1728—1738. https://doi.org/10.1016/S0140-6736(12)60282-7
  4. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol. 2012;153(2):209-213.e202. https://doi.org/10.1016/j.ajo.2011.10.016
  5. Sloan FA, Hanrahan BW. The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol. 2014;132(4):456-463. https://doi.org/10.1097/IAE.0b013e3181f04991
  6. Yang Sh., Zhao J., Sun X. Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Design, Development and Therapy. 2016;10:1857-1867. https://doi.org/10.1097/IAE.0b013e31826b6763
  7. CATT Research Group, Martin DF, Maguire MG, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med. 2011;364(20):1897-908. https://doi.org/10.1056/NEJMoa1102673
  8. Chakravarthy U, Harding SP, Rogers CA et al. Ranibizumab versus beva-cizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 2012;119:1399-1411.
https://doi.org/10.1016/S0161-6420(13)38012-9
  9. Heier JS, Brown DM, Chong V et al. VIEW 1 and VIEW 2 Study Groups. Ophthalmology. 2012;119(12):2537-2548. https://doi.org/10.1016/j.ophtha.2012.09.006
  10. Amoaku WM, Chakravarthy U, Gale R, et al. De ning response to anti-VEGF therapies in neovascular AMD. Eye (Lond). 2015;29(6):721-731. https://doi.org/10.1016/j.ophtha.2014.08.048
  11. Pauleikhoff D, Loffert D, Spital G, Radermacher M, Dohrmann J, Lommatzsch A, Bird AC. Pigment epithelial detachment in the elderly. Clinical differentiation, natural course and pathogenetic implications. Graefes Arch Clin Exp Ophthalmol. 2002;240:533-538. https://doi.org/10.1007/s00417-002-0505-8
  12. Lommatzsch A, Heimes B, Gutfleisch M, Spital G, Zeimer M, Pauleikhoff D. Serous pigment epithelial detachment in age-related macular degeneration: comparison of different treatments. Eye (Lond). 2009;23:2163-2168. https://doi.org/10.1136/bjo.2007.118497
  13. Martin DF, Maguire MG, Fine SL et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology. 2012;119:1388-1398. https://doi.org/10.1016/j.ophtha.2012.03.053
  14. van Asten F, Rovers MM, Lechanteur YT, et al. Predicting non-response to ranibizumab in patients with neovascular age-related macular degeneration. Ophthalmic Epidemiol. 2014;21(6):347-355. https://doi.org/10.3109/09286586.2014.949010
  15. Sloan FA, Hanrahan BW. The effects of technological advances on outcomes for elderly persons with exudative age-related macular degeneration. JAMA Ophthalmol. 2014;132(4):456-463. https://doi.org/10.1097/IAE.0b013e3181f04991
  16. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444. https://doi.org/10.1056/NEJMoa062655
  17. Rosenfeld PJ, Brown DM, Heier JS, et al; MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431. https://doi.org/10.1016/j.ajo.2010.01.039
  18. Sarraf D, London NJ, Khurana RN et al. Ranibizumab treatment for pigment epithelium detachment secondary to neovascular age-related macular degeneration: post hoc analysis of the HARBOR study. Ophthalmology. 2016;123(10):2213-2224. https://doi.org/10.1016/j.ophtha.2016.07.007
  19. Schmidt-Erfurth U, Waldstein SM, Deak GG, Kundi M, Simader C. Pigment epithelial detachment followed by retinal cystoid degeneration leads to vision loss in treatment of neovascular age-related macular degeneration. Ophthalmology. 2015;122:822-832. https://doi.org/10.1016/j.ophtha.2014.11.017
  20. Clemens CR, Bastian N, Alten F, Milojcic C, Heiduschka P, Eter N. Prediction of retinal pigment epithelial tear in serous vascularized pigment epithelium detachment. Acta Ophthalmol. 2014;92(1):e50-6. https://doi.org/10.1111/aos.12234
  21. Wolf A, Ruping J, Neubauer AS et al. Alterations of vascular pigment epithelium detachments associated with age-related macular degeneration during upload with intravitreal ranibizumab. Retina. 2013;33:1843-1849. https://doi.org/10.1097/IAE.0b013e318287d9be
  22. Chan CK, Abraham P, Sarraf D, Nuthi AS, Lin SG, Mc Cannel CA. Earlier therapeutic effects associated with high dose (2.0 mg) Ranibizumab for treatment of vascularized pigment epithelial detachments in age-related macular degeneration. Eye. 2015;29:80-87. https://doi.org/10.1038/eye.2014.233
  23. Inoue M, Arakawa A, Yamane S & Kadonosono K. Variable response of vascularized pigment epithelial detachments to ranibizumab based on lesion subtypes, including polypoidal choroidal vasculopathy. Retina. 2013;33:990-997. https://doi.org/10.1097/IAE.0b013e3131827557
  24. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K; SEVEN-UP Study Group. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(11):2292-2299. https://doi.org/10.1016/j.ophtha.2013.03.046
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.